Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Old Dominion Freight Line Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.1 (market cap $29.60B), while Old Dominion Freight Line Inc trades at $212.63 (market cap $43.43B). The key difference: Old Dominion Freight Line Inc is the larger of the two by market cap, and Old Dominion Freight Line Inc pays a 0.55% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ODFL | |
|---|---|---|
Market Cap | $29.60B | $43.43B |
Sector | Health | Industrials |
52-Week High | $491.22 | $248.73 |
52-Week Low | $205.48 | $126.29 |
Enterprise Value | $27.56B | $43.17B |
Dividend Yield | — | 0.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
ODFL trades at $212.55, down 1.76% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 19.44% net margins and 24.82% ROE, though valuation metrics remain elevated with a P/E of 40.28. Recent Q2 2026 earnings of $1.68 per share exceeded expectations, driven by yield improvements and cost discipline amid ongoing freight market pressures.
The stock faces headwinds from premium valuation and mixed analyst sentiment (33% buy, 56% hold), but strong fundamentals and consistent earnings outperformance provide support. Key risks include freight volume recovery uncertainty and execution pressure given high expectations. The consensus price target of $239.85 suggests 13% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
